Scientists train Patients' own cells to hunt deadly pancreatic cancer
NCT ID NCT04146298
Summary
This early-stage trial is testing a new treatment for advanced pancreatic cancer. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack cancer cells with a specific KRAS G12V mutation, and then infuse them back into the patient. The study aims to see if this approach is safe and if it can shrink tumors in people whose cancer has this mutation and a specific genetic marker (HLA-A*11:01).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, 200433, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.